| Patent Number |
Title Of Patent |
Date Issued |
| RE30872 |
Process for producing 2-keto-L-gulonic acid |
February 23, 1982 |
| 2-Keto-L-gulonic acid is prepared from 2,5-diketo-D-gluconic acid through microbial conversion. The 2-keto-L-gulonic acid producing microorganism used for this microbial conversion includes strains which belong to genera of Brevibacterium, Arthrobacter, Micrococcus, Staphylococcus, Pseud |
| H328 |
Purification of cephalosporins |
September 1, 1987 |
| A process for purifying oxacephalosporins which comprises contacting an aqueous solution of oxacephalosporin carboxylic acid (at pH lower than its pKa) with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C. large |
| 7612225 |
Crystal of triterpene derivative |
November 3, 2009 |
| Disclosed herein are a novel crystal of a novel triterpene derivative, a method for producing the crystals, and a pharmaceutical preparation obtained by using the crystals.The novel crystal is a crystal of a compound (I) of the formula (I): ##STR00001## |
| 7601746 |
Compounds exhibiting thrombopoietin receptor agonism |
October 13, 2009 |
| A compound represented by the general formula (I): ##STR00001## wherein R.sup.1 is a hydrogen atom, a halogen atom, or the like; R.sup.2, R.sup.3, and R.sup.4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy |
| 7598372 |
Synthesis of core sugar chain structure of asparagine-linked glycoprotein |
October 6, 2009 |
| It is intended to chemically synthesize the trisaccharide moiety at the reducing end in the core sugar chain structure of an asparagine-linked glycoprotein. By using a highly inexpensive natural polysaccharide having a mannose.beta.-1,4-bond as the starting material, a .beta.-1,4-glycosi |
| 7582665 |
Compounds exhibiting thrombopoietin receptor agonism |
September 1, 2009 |
| Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X.sup.1--Y.sup.1-Z.sup.1-W.sup.1 (I) wherein X.su |
| 7576198 |
Integrase inhibitors containing aromatic heterocycle derivatives |
August 18, 2009 |
| A compound of the formula (I): ##STR00001## wherein X is hydroxy or the like; Y is --C(.dbd.R.sup.2)--R.sup.3--R.sup.4 wherein R.sup.2 and R.sup.3 is oxygen atom or the like, R.sup.4 is hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or the like; Z is hydro |
| 7572579 |
Screening method for a ribonuclease H inhibitor of a reverse transcriptase |
August 11, 2009 |
| A screening method for a compound which inhibits a ribonuclease H activity of a reverse transcriptase which includes incubating a substrate with an appropriate primer hybridized to an appropriate template, a metal ion and a reverse transcriptase to form a complex, adding a test substance |
| 7550463 |
Carbamoylpyridone derivatives having inhibitory activity against HIV integrase |
June 23, 2009 |
| An object of the present invention provides a novel compound having the anti-viral activity, particularly, the HIV integrase inhibitory activity, and a drug containing the same, particularly, an anti-HIV drug.There is provided a compound represented by the formula: ##STR00001## wherein, |
| 7547800 |
Process for trans-4-amino-1-cyclohexanecarboxylic acid derivatives |
June 16, 2009 |
| A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: ##STR00001## wherein R.sup.1 and R.sup.2 are each independently lower alkyl. |
| 7534897 |
Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
May 19, 2009 |
| A compound having CRTH2 receptor antagonism, represented by the following formula (I). The compound is useful for the treatment of allergic diseases having a relation to eosinophils and the like.A compound of the formula (I): ##STR00001## wherein a group represented by the formula: |
| 7534892 |
Sulfonamide compound |
May 19, 2009 |
| The present invention provides a compound of the formula (I): ##STR00001## (wherein, R.sup.1 is ethyl optionally substituted by halogen or amino optionally substituted by lower alkyl, R.sup.2 and R.sup.3 are each independently hydrogen or lower alkyl, X is cycloalkylene, lower alkylene |
| 7534582 |
Method for measuring the amount of natriuretic peptides in a sample |
May 19, 2009 |
| A method for accurately measuring an amount of natriuretic peptides in a sample that has stood for at least 24 hours, in a plastic tube or a tube coated with silicone. This method makes it possible to measure natriuretic peptides stably and conveniently. Also provided is a method for |
| 7459580 |
Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives |
December 2, 2008 |
| A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: ##STR00001## wherein R.sup.1 and R.sup.2 are each independently lower alkyl. |
| 7429593 |
Utilities of amide compounds |
September 30, 2008 |
| Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments.Compounds of formula (I): ##STR00001## in which ring A and Ar.sup.1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each |
| 7420053 |
2-imino-1,3-thiazine derivatives |
September 2, 2008 |
| The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use. |
| 7384928 |
Broad spectrum cephem compounds |
June 10, 2008 |
| A compound of the formula: ##STR00001## (wherein, T is S, SO or O; X is halogen, CN, carbamoyl optionally substituted with lower alkyl, lower alkyl, lower alkoxy, or lower alkylthio; A is substituted lower alkylene (wherein the substituent is optionally substituted mono lower alkyl, |
| 7371818 |
Polypeptide and DNA thereof |
May 13, 2008 |
| A novel chordin-like polypeptide is found out in a protein secreted from mesenchymal stem cells. This polypeptide is useful as a cancer marker and a remedy for parotid cancer, lung cancer, esophagus cancer, gastric cancer, duodenal carcinoma, kidney cancer, ureteral cancer, testicular |
| 7361737 |
Mouse CXC chemokine receptor |
April 22, 2008 |
| The present invention pertains to a DNA encoding a polypeptide including an entire sequence of the amino acid sequence as shown by SEQ ID NO: 2 or a partial sequence thereof, or a polypeptide including the polypeptide described above, wherein any of the polypeptides has an activity of a |
| 7358249 |
Heterocyclic compounds having inhibitory activity against HIV integrase |
April 15, 2008 |
| A heterocyclic compound of the formula (I): ##STR00001## wherein B.sup.1 is --C(R.sup.2).dbd. or --N.dbd.; R.sup.1' is H, etc.; one of R.sup.1 and R.sup.2 is -Z.sup.1-Z.sup.2-Z.sup.3-R.sup.5 wherein Z.sup.1 and Z.sup.3 are independently single bond, optionally substituted alkylene, etc. |
| 7314950 |
Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative |
January 1, 2008 |
| A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: ##STR00001## wherein R.sup.1 and R.sup.2 are each independently lower alkyl. |
| 7265130 |
NPY Y5 antagonist |
September 4, 2007 |
| The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): ##STR00001## wherein R.sup.1 is lower alkyl, cycloalkyl or the like, R.sup.2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower a |
| 7226729 |
Method for inhibiting degradation of brain natriuretic peptides |
June 5, 2007 |
| A method for inhibiting the degradation of mammalian natriuretic peptides, in particular BNP, by using containers wherein the face coming into contact with specimens are made of silicone or plastics. This material inhibits the activation of a substance, which in turn, degrades the pe |
| 7223882 |
Process for producing triterpene derivative |
May 29, 2007 |
| A process for a preparation of Compound (V), a pharmaceutically acceptable salt or a solvate thereof, said process comprising the steps represented by the following formula: ##STR00001## wherein R.sup.1 and R.sup.2 are each independently C1 C8 alkyl. |
| 7220783 |
Para-terphenyl compounds |
May 22, 2007 |
| The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or |
| 7214832 |
Processes for the preparation of bicyclic aminoalcohols |
May 8, 2007 |
| The present invention provides a process for the preparation of a bicyclic aminoalcohol which comprises reacting a starting compound, nopinone (I), with XCH.sub.2COOR.sup.1 wherein X is halogen, and R.sup.1 is alkyl, in the presence of an additive and a base to produce a compound (II), |
| 7211380 |
Physiologically active polypeptide and DNA |
May 1, 2007 |
| A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, a |
| 7189857 |
Processes for the preparation of oxo-oxazoline or alloamino acid derivatives |
March 13, 2007 |
| A method for producing a compound represented by the general formula (I-A) or the general formula (I-B), comprising the following step: ##STR00001## wherein R.sup.1 is an optionally substituted lower alkyl, and the like; R.sup.2 is a lower alkyl or an optionally substituted aralkyl, and |
| 7183275 |
2-imino-1,3-thiazine derivatives |
February 27, 2007 |
| The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use. |
| 7169931 |
Cyclic compounds exhibiting thrombopoietin receptor agonism |
January 30, 2007 |
| Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X.sup.1--Y.sup.1-Z.sup.1 (I) wherein X.sup.1 is |
| 7148237 |
Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity |
December 12, 2006 |
| A compound of the formula (I): ##STR00001## wherein Z.sup.4, Z.sup.5 and Z.sup.9 each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; R.sup.A is a group of the formula: ##STR00002## (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory |
| 7129352 |
Crystalline salts of 7-'4-(4-fluorophenyl) -6-isopropyl-2-'methyl (methylsulfonyl) amino!pyrimid |
October 31, 2006 |
| The invention relates to crystalline salts of the compound (E)-7-[4-(4-fluorophenyl)isopropyl-2-[methyl(methylsulfonyl)amino]pyrimid- in-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid of formula (I), as well as processes for their manufacture, pharmaceutical compositions containing them |
| 7129256 |
Antiparkinsonism drugs |
October 31, 2006 |
| A compound represented by the formula: ##STR00001## wherein A is thiazolyl or the like, X is a bond or the like, m is an integer of 0 to 4, Y is optionally substituted alkyl or the like, Z is a substituent represented by the formula: ##STR00002## wherein R.sup.3 is hydrogen atom or |
| 7118903 |
L-methionine $g(g)-lyase with modified function |
October 10, 2006 |
| An L-methionine .gamma.-lyase having modified function which is obtained by structurally stabilizing natural L-methionine .gamma.-lyase by analyzing the structure of crystals thereof by using X-ray, estimating an amino acid sequence concerning its substrate specificity and varying am |
| 7105564 |
Pharmaceutical composition comprising a dual antagonist against PGD.sub.2/TXA.sub.2 receptors ha |
September 12, 2006 |
| The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D.sub.2 receptor and pharmaceutical compositions comprising them.A compound of the formula (I): ##STR00001## wherein R.sup.1 is --CH.sub.2--CH.dbd.CH- |
| 7101915 |
P-terphenyl compounds |
September 5, 2006 |
| The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or |
| 7098237 |
Remedies for ischemia reperfusion injury |
August 29, 2006 |
| A composition for treating or preventing ischemia reperfusion injury which contains an sPLA.sub.2 inhibitor as an active ingredient. |
| 7098201 |
Heteroaromatic derivatives having an inhibitory activity against HIV integrase |
August 29, 2006 |
| A compound of the formula (I): ##STR00001## wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is --COOR.sup.A wherein R.sup.A is hydrogen or ester residue, --CONR.sup.BR.sup.C wherein R.sup.B and R.sup.C each is independently hydrogen or amide residue, opti |
| 7087764 |
Process for producing arylsulfenyl halide |
August 8, 2006 |
| A process for producing a compound of the formula (II): ##STR00001## wherein Hal.sup.1 represents halogen and R.sup.1 and R.sup.2 each independently represents halogen, alkyl, alkoxy, nitro or cyano, which comprises allowing a halogenating agent to react with a compound of the formul |
| 7084136 |
Drug composition antagonistic to both PGD.sub.2/TXA.sub.2 receptors |
August 1, 2006 |
| A compound of the formula (I): ##STR00001## wherein A is alkylene optionally having an unsaturated bond; R is --C(.dbd.O)--R.sup.1; R.sup.1 is hydroxy or the like; m is 0 or 1; p is 0 or 1; X.sup.1 and X.sup.3 are each independently optionally substituted aryl or optionally substituted |
| 7074836 |
Para-terphenyl compounds |
July 11, 2006 |
| The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or |
| 7074616 |
Mouse CXC chemokine receptor |
July 11, 2006 |
| The present invention pertains to a DNA encoding a polypeptide comprising an entire sequence of the amino acid sequence as shown by SEQ ID NO:2 of Sequence Listing or a partial sequence thereof, or a polypeptide comprising the polypeptide described above, wherein any of the polypepti |
| 7049437 |
Synthetic process and crystal form of condensed imidazopyridine derivatives |
May 23, 2006 |
| The present invention provides a process of a compound of the formula (I): ##STR00001## wherein R is heteroaryl or the like, ring A is a heteroalicyclic group or the like comprising reacting a compound of the formula (II): ##STR00002## wherein Hal is halogen and the other symbols a |
| 7026334 |
Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonis |
April 11, 2006 |
| Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: ##STR00001## wherein X.sup.1 is optionally subst |
| 7026318 |
Compounds exhibiting X-type sPLA.sub.2 inhibiting effect |
April 11, 2006 |
| A compound represented by the general formula: ##STR00001## wherein R.sup.20 is --CH.sub.2COOH and the like; R.sup.21 is --COCONH.sub.2 and the like; R.sup.22 is C4 C6 alkyl; and the like; R.sup.23 is --CH.sub.2--R.sup.18 wherein R.sup.18 is aryl and the like; R.sup.24 is hydrogen |
| 7018796 |
Preincubation assay methods |
March 28, 2006 |
| Pseudo-positive data can be reduced by incubating a solution containing an enzyme in the absence of a test substance and a substrate of the enzyme. |
| 7011951 |
Apoptosis-associated gene |
March 14, 2006 |
| A polypeptide possessing an action of causing chromatin condensation; a sense nucleic acid encoding the polypeptide; an antisense nucleic acid thereof, a probe or primer capable of specifically binding to the nucleic acid; an antibody or a fragment thereof against the polypeptide; an age |
| 7008954 |
Th2 differentiation inhibitors |
March 7, 2006 |
| The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (I): ##STR00001## wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a |
| 6987187 |
Process for preparation of amidine derivatives |
January 17, 2006 |
| A process for producing amidine derivatives represented by the following reaction scheme, characterized in that the reactions of steps 1 and 3 are conducted in acetonitrile and the reaction of step 2 is conducted in acetone. ##STR00001## |
| 6982157 |
Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[meth- ylsulfonyl)amino] pyr |
January 3, 2006 |
| The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)a- mino]pyrimidin-5-yl](3R,5S)-3,5 -dihydroxyhept-6-enoic acid or a pharmaceu |
